In biopharmaceutical manufacturing, researchers report an engineered protein breakdown system designed to improve drug-free selection of high-producing CHO cells. The work targets one of the biggest manufacturing bottlenecks: efficiently identifying rare, productive cell populations without adding costly or complicating selection steps. The report frames the platform as enabling faster and more scalable screening of producer lines. It positions the method as an engineering solution to selection pressure—aimed at improving yield while keeping processes simpler. While not a clinical biotech advance, the manufacturing impact is direct: selection efficiency can reduce development time and improve consistency of production cell lines. For industry readers, the takeaway is that selection technologies remain a key lever for bioprocess optimization, especially as developers move toward tighter timelines and increased biologics output.